JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 4, 2007; DOI: 10.1124/jpet.106.114421

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.114421v1
321/1/327    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhalla, A. K
Right arrow Articles by Belardinelli, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhalla, A. K
Right arrow Articles by Belardinelli, L.


Received for publication September 22, 2006.
Revised December 29, 2006.
Accepted for publication January 2, 2007.

Anti-lipolytic Activity of a Novel Partial A1 Adenosine Receptor Agonist Devoid of Cardiovascular Effects: Comparison with Nicotinic Acid

Arvinder K Dhalla 1*, Melissa Santikul 1, Michelle Smith 1, Mei-Yee Wong 1, John C Shryock 1, Luiz Belardinelli 1

1 CV Therapeutics, Inc

* Address correspondence to: E-mail: arvinder.dhalla{at}cvt.com

Abstract

Elevated lipolysis and circulating free fatty acid (FFA) levels have been linked to the pathogenesis of insulin resistance. A1 adenosine receptor agonists are potent inhibitors of lipolysis. Several A1 agonists have been tested as potential anti-lipolytic agents; however, their effect on the cardiovascular system remains a potential problem for development of these agents as drugs. In the present study we report that CVT-3619, a novel partial A1 receptor agonist, significantly reduces circulating FFA levels without any effect on heart rate and blood pressure in awake rats. Rats were implanted with indwelling arterial and venous cannulas to obtain serial blood samples, record arterial pressure, and administer drug. CVT-3619 decreased FFA levels in a dose-dependent manner at doses from 1 up to 10 mg/kg. The FFA lowering effect was blocked by A1 receptor antagonist, DPCPX. Triglyceride (TG) levels were also significantly reduced by CVT-3619 treatment in the absence and presence of Triton. Tachyphylaxis of the anti-lipolytic effect of CVT-3619 (1 mg/kg, iv bolus) was not observed with three consecutive treatments. An acute reduction of FFA by CVT-3619 was not followed by a rebound increase of FFA as seen with nicotinic acid. The potency of insulin to decrease lipolysis was increased 4-fold (p<0.01) in the presence of CVT-3619 (0.5 mg/kg). In summary, CVT-3619 is an orally bioavailable A1 agonist which lowers circulating FFA and TG levels by inhibiting lipolysis. CVT-3619 has anti-lipolytic effects at doses that do not elicit cardiovascular effects.


Key words: A1 adenosine receptor, Anti-lipolytic, CVT-3619, Free Fatty Acids, Partial Agonist, Triglycerides


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. K. Dhalla, M. Y. Wong, P. J. Voshol, L. Belardinelli, and G. M. Reaven
A1 adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents
Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1358 - E1363.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.